TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transcranial Magnetic Stimulation and/or Neurofunctional Electrical Acupuncture in the Rehabilitation of Patients With Myofascial Chronic Pain
Brief Summary: To evaluate the hypothesis: the effects of repetitive transcranial magnetic (rTMS) stimulation and/or peripheral stimulation (neurofunctional electrical acupuncture) treatments are more effective in pain relief than placebo-sham in patients with myofascial chronic pain.


Options:
A: Arm Label: Real tDCS; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: Sham tDCS; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Real tDCS | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham tDCS
B: Arm Label: Active tDCS; Type: EXPERIMENTAL; Interventions: Device: Transcranial direct current stimulation (tDCS) | Arm Label: Sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: Transcranial direct current stimulation (tDCS) | Intervention Type: DEVICE; Name: Transcranial direct current stimulation (tDCS); Assigned to Arm(s): Active tDCS, Sham tDCS
C: Arm Label: Group I; Type: ACTIVE_COMPARATOR; Interventions: Device: Real tDCS | Arm Label: Group II; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: Real tDCS; Assigned to Arm(s): Group I | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group II
D: Arm Label: Both Sham rTMS and Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham rTMS, Device: Sham Neuroacupuncture | Arm Label: Active rTMS and sham Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Active rTMS, Device: Sham Neuroacupuncture | Arm Label: Sham rTMS and Active Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham rTMS, Device: Active Neuroacupuncture | Arm Label: Both Active rTMS and Neuroacupuncture; Type: ACTIVE_COMPARATOR; Interventions: Device: Active rTMS, Device: Active Neuroacupuncture | Intervention Type: DEVICE; Name: Active rTMS; Assigned to Arm(s): Active rTMS and sham Neuroacupuncture, Both Active rTMS and Neuroacupuncture | Intervention Type: DEVICE; Name: Sham rTMS; Assigned to Arm(s): Both Sham rTMS and Neuroacupuncture, Sham rTMS and Active Neuroacupuncture | Intervention Type: DEVICE; Name: Active Neuroacupuncture; Assigned to Arm(s): Both Active rTMS and Neuroacupuncture, Sham rTMS and Active Neuroacupuncture | Intervention Type: DEVICE; Name: Sham Neuroacupuncture; Assigned to Arm(s): Active rTMS and sham Neuroacupuncture, Both Sham rTMS and Neuroacupuncture

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transcranial Magnetic Stimulation and/or Neurofunctional Electrical Acupuncture in the Rehabilitation of Patients With Myofascial Chronic Pain
Brief Summary: To evaluate the hypothesis: the effects of repetitive transcranial magnetic (rTMS) stimulation and/or peripheral stimulation (neurofunctional electrical acupuncture) treatments are more effective in pain relief than placebo-sham in patients with myofascial chronic pain.


Options:
A: Arm Label: Both Sham rTMS and Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham rTMS, Device: Sham Neuroacupuncture | Arm Label: Active rTMS and sham Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Active rTMS, Device: Sham Neuroacupuncture | Arm Label: Sham rTMS and Active Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham rTMS, Device: Active Neuroacupuncture | Arm Label: Both Active rTMS and Neuroacupuncture; Type: ACTIVE_COMPARATOR; Interventions: Device: Active rTMS, Device: Active Neuroacupuncture | Intervention Type: DEVICE; Name: Active rTMS; Assigned to Arm(s): Active rTMS and sham Neuroacupuncture, Both Active rTMS and Neuroacupuncture | Intervention Type: DEVICE; Name: Sham rTMS; Assigned to Arm(s): Both Sham rTMS and Neuroacupuncture, Sham rTMS and Active Neuroacupuncture | Intervention Type: DEVICE; Name: Active Neuroacupuncture; Assigned to Arm(s): Both Active rTMS and Neuroacupuncture, Sham rTMS and Active Neuroacupuncture | Intervention Type: DEVICE; Name: Sham Neuroacupuncture; Assigned to Arm(s): Active rTMS and sham Neuroacupuncture, Both Sham rTMS and Neuroacupuncture
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Transcranial stimulation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Transcranial stimulation | Intervention Type: OTHER; Name: Transcranial stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Transcranial stimulation; Assigned to Arm(s): 2
C: Arm Label: Active TMS; Type: ACTIVE_COMPARATOR; Interventions: Device: Active TMS | Arm Label: Sham TMS; Type: SHAM_COMPARATOR; Interventions: Device: Sham TMS | Intervention Type: DEVICE; Name: Active TMS; Assigned to Arm(s): Active TMS | Intervention Type: DEVICE; Name: Sham TMS; Assigned to Arm(s): Sham TMS
D: Arm Label: Group I; Type: ACTIVE_COMPARATOR; Interventions: Device: Real tDCS | Arm Label: Group II; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: Real tDCS; Assigned to Arm(s): Group I | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group II

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Ultrasound Guided Femoral Nerve Blockade and Standard Parenteral Opioid Pain Management Alone in Patients With Hip Fracture in the Emergency Department
Brief Summary: The goal of the study is to evaluate whether pain control achieved by Ultrasound Guided Femoral Nerve Blockade (USFNB) is equal in efficacy to standard pain management practice of parenteral injection of opioid pain medication in patients presenting to the emergency department (ED) with hip fracture.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Fascia iliaca block; Type: EXPERIMENTAL; Interventions: Procedure: Fascia iliaca block arm | Intervention Type: PROCEDURE; Name: Fascia iliaca block arm; Assigned to Arm(s): Fascia iliaca block
B: Arm Label: ultra-sound guided femoral nerve block; Type: EXPERIMENTAL; Interventions: Other: ultra-sound guide, Drug: bupivacaine | Arm Label: standard of care- IV morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: morphine | Intervention Type: OTHER; Name: ultra-sound guide; Assigned to Arm(s): ultra-sound guided femoral nerve block | Intervention Type: DRUG; Name: bupivacaine; Assigned to Arm(s): ultra-sound guided femoral nerve block | Intervention Type: DRUG; Name: morphine; Assigned to Arm(s): standard of care- IV morphine
C: Arm Label: Compartment Block; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ropivacaine, Drug: Epinephrine | Arm Label: Infiltration; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ropivacaine, Drug: Epinephrine | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): Compartment Block, Infiltration | Intervention Type: DRUG; Name: Epinephrine; Assigned to Arm(s): Compartment Block, Infiltration
D: Arm Label: Standard Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Continuous fascia iliaca block; Type: EXPERIMENTAL; Interventions: Procedure: Continuous fascia iliaca block, Drug: Ropivacaine | Intervention Type: PROCEDURE; Name: Continuous fascia iliaca block; Assigned to Arm(s): Continuous fascia iliaca block | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): Continuous fascia iliaca block

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Brief Summary: 24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.


Options:
A: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Iloprost, Drug: Bosentan | Arm Label: monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Iloprost; Assigned to Arm(s): Combination therapy | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Combination therapy, monotherapy
B: Arm Label: Macitentan; Type: EXPERIMENTAL; Interventions: Drug: Macitentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macitentan; Assigned to Arm(s): Macitentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Investigational treatment; Type: EXPERIMENTAL; Interventions: Drug: Macitentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Macitentan; Assigned to Arm(s): Investigational treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction
Brief Summary: Proven treatments exist that improve quality of life and reduce the risk of repeat heart attacks or death amongst persons who have already had one heart attack. These treatments include medications and supervised cardiac rehabilitation programs. Unfortunately, research shows that many people who have had a heart attack do not stick with these treatments and therefore cannot benefit. This quality improvement research program seeks to understand the impact of interventions that could be readily implemented at scale by entire health systems or organizations wishing to improve adherence to proven treatments. Specifically, the trial will test whether providing Ontario-based patients (and their health professionals) with repeated educational reminders delivered via post and phone will help improve the use of medications or attendance at cardiac rehabilitation. During the project, the types of patients who are most responsive will be identified as will the most cost-effective strategy for delivering reminders. The trial team are partnering in this project with health system decision makers who have an interest in using the results to create standard operating procedures that could benefit patients across the province.


Options:
A: Arm Label: Baduanjin exercise group; Type: EXPERIMENTAL; Interventions: Other: Baduanjin exercise | Arm Label: usual exercise control group; Type: ACTIVE_COMPARATOR; Interventions: Other: aerobic exercise | Intervention Type: OTHER; Name: Baduanjin exercise; Assigned to Arm(s): Baduanjin exercise group | Intervention Type: OTHER; Name: aerobic exercise; Assigned to Arm(s): usual exercise control group
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual care + letters; Type: EXPERIMENTAL; Interventions: Behavioral: Usual care + letters | Arm Label: Usual care + letters + automated calls; Type: EXPERIMENTAL; Interventions: Behavioral: Usual care + letters + automated calls | Intervention Type: BEHAVIORAL; Name: Usual care + letters; Assigned to Arm(s): Usual care + letters | Intervention Type: BEHAVIORAL; Name: Usual care + letters + automated calls; Assigned to Arm(s): Usual care + letters + automated calls
C: Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): N/A
D: Arm Label: 12 week exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Structured exercise training | Arm Label: Conventional Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Structured exercise training; Assigned to Arm(s): 12 week exercise training

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International Register of Open Abdomen
Brief Summary: To evaluate the different indications to Open Abdomen, the different techniques used to perform it, it's management, it's definitive closure and mortality rates linked to the different variables. Moreover to evaluate the 1 month and 1 year follow up in patients underwent to Open Abdomen.


Options:
A: Arm Label: "Stampede" VAC; Type: ACTIVE_COMPARATOR; Interventions: Device: "Stampede" VAC | Arm Label: KCI AbThera; Type: EXPERIMENTAL; Interventions: Device: KCI AbThera | Intervention Type: DEVICE; Name: KCI AbThera; Assigned to Arm(s): KCI AbThera | Intervention Type: DEVICE; Name: "Stampede" VAC; Assigned to Arm(s): "Stampede" VAC
B: Arm Label: Open Abdomen patients; Type: N/A; Interventions: Procedure: Open abdomen procedure | Intervention Type: PROCEDURE; Name: Open abdomen procedure; Assigned to Arm(s): Open Abdomen patients
C: Arm Label: Open Abdomen - Vacuum Pack; Type: EXPERIMENTAL; Interventions: Device: Vacuum Pack | Arm Label: Double Sylo Bag - Mesh Protocol; Type: ACTIVE_COMPARATOR; Interventions: Device: Double Sylo Bag - Mesh Protocol | Intervention Type: DEVICE; Name: Vacuum Pack; Assigned to Arm(s): Open Abdomen - Vacuum Pack | Intervention Type: DEVICE; Name: Double Sylo Bag - Mesh Protocol; Assigned to Arm(s): Double Sylo Bag - Mesh Protocol
D: Arm Label: Open Abdomen Management with ANPPT dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Open Abdomen Management with ANPPT dressing | Arm Label: Closed Abdomen Management; Type: SHAM_COMPARATOR; Interventions: Other: Closed Abdomen Management | Intervention Type: DEVICE; Name: Open Abdomen Management with ANPPT dressing; Assigned to Arm(s): Open Abdomen Management with ANPPT dressing | Intervention Type: OTHER; Name: Closed Abdomen Management; Assigned to Arm(s): Closed Abdomen Management

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimization of the Flare Management in Rheumatoid Arthritis (RA) by Implementing Patient-driven Systematic Changes to the RA Ambulatory Care Stream
Brief Summary: The purpose of this study is to determine how best to monitor for flares in patients with rheumatoid arthritis (RA).


Options:
A: Arm Label: PCI Group; Type: OTHER; Interventions: Other: Patient Concerns Inventory | Arm Label: Non PCI Group; Type: OTHER; Interventions: Other: No Patient Concerns Inventory | Intervention Type: OTHER; Name: Patient Concerns Inventory; Assigned to Arm(s): PCI Group | Intervention Type: OTHER; Name: No Patient Concerns Inventory; Assigned to Arm(s): Non PCI Group
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: HITCM+CP | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HITCM only | Intervention Type: BEHAVIORAL; Name: HITCM+CP; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: HITCM only; Assigned to Arm(s): Arm 2
C: Arm Label: FLARE Intervention Group; Type: OTHER; Interventions: Other: FLARE Intervention Group | Arm Label: Standard of Care (SOC) Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: FLARE Intervention Group; Assigned to Arm(s): FLARE Intervention Group
D: Arm Label: Feedback Group; Type: EXPERIMENTAL; Interventions: Behavioral: Communication Feedback Form for Patients with Serious Illness | Arm Label: Comparison/Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication Feedback Form for Patients with Serious Illness; Assigned to Arm(s): Feedback Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Brief Summary: Study of Pazopanib and weekly Paclitaxel in patients with platinum resistant/refractory ovarian cancer who relapse during bevacizumab maintenance.


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Arm C
B: Arm Label: Patupilone; Type: EXPERIMENTAL; Interventions: Drug: EPO906 (Patupilone) | Arm Label: doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: doxorubicin | Intervention Type: DRUG; Name: EPO906 (Patupilone); Assigned to Arm(s): Patupilone | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): doxorubicin
C: Arm Label: Pazopanib/Paclitaxel association; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Paclitaxel | Arm Label: Paclitaxel alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib/Paclitaxel association | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel alone, Pazopanib/Paclitaxel association
D: Arm Label: Olaparib 300mg tablets; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match olaparib 300mg | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib 300mg tablets | Intervention Type: DRUG; Name: Placebo to match olaparib 300mg; Assigned to Arm(s): Placebo tablets

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Brief Summary: Study of Pazopanib and weekly Paclitaxel in patients with platinum resistant/refractory ovarian cancer who relapse during bevacizumab maintenance.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Niraparib | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab, Drug: Niraparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Arm 1, Arm 2
B: Arm Label: Pazopanib/Paclitaxel association; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Paclitaxel | Arm Label: Paclitaxel alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib/Paclitaxel association | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel alone, Pazopanib/Paclitaxel association
C: Arm Label: A: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: C: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): B: Olaparib, C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A: Paclitaxel
D: Arm Label: A (reference); Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: B (concurrent cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Arm Label: C (concurrent and maintenance cediranib); Type: ACTIVE_COMPARATOR; Interventions: Drug: cediranib | Intervention Type: DRUG; Name: cediranib; Assigned to Arm(s): B (concurrent cediranib), C (concurrent and maintenance cediranib)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Brief Summary: Study of Pazopanib and weekly Paclitaxel in patients with platinum resistant/refractory ovarian cancer who relapse during bevacizumab maintenance.


Options:
A: Arm Label: Olaparib tablets p.o. 300mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets p.o. twice daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olaparib 300mg tablets | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib tablets p.o. 300mg twice daily, Placebo tablets p.o. twice daily
B: Arm Label: Pazopanib/Paclitaxel association; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Paclitaxel | Arm Label: Paclitaxel alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib/Paclitaxel association | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel alone, Pazopanib/Paclitaxel association
C: Arm Label: Combination navicixizumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Arm Label: Paclitaxel monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Xerna™ TME Panel | Arm Label: Navicixizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Intervention Type: DRUG; Name: navicixizumab; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy | Intervention Type: DEVICE; Name: Xerna™ TME Panel; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy, Paclitaxel monotherapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1

Answer: B